Millennium Management
PRTK

Millennium Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Millennium Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-200,000
Closed -$3.85M – 3981
2017
Q1 		$3.85M Buy
+200,000
New +$3.15M 0.01% 1610

Other funds holding PRTK

NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Millennium Management's PRTK Position: Q2 2023 in Review

Millennium Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2023, closing a stake of 71,470 shares — an estimated $182K sold.

Millennium Management first reported a position in PRTK in Q2 2013 and held it in 23 quarters. The position peaked at $9.86M in Q1 2017. 66 funds tracked by Wall St. Rank hold PRTK as of Q2 2023.

  • Millennium Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Millennium Management sold 71,470 Paratek Pharmaceuticals, Inc. shares in Q2 2023, an estimated $182K.
  • Millennium Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 23 quarters.
  • Millennium Management's Paratek Pharmaceuticals, Inc. position peaked at $9.86M in Q1 2017.
  • 66 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2023.

Based on Millennium Management's 13F filing for Q2 2023, filed 14 Aug 2023.